Five CAR-T Therapies Included in China's First Commercial Insurance Innovative Drug Directory

On December 7, the first edition of the Commercial Insurance Innovative Drug List was released in Guangzhou. All five CAR-T therapies that entered the preliminary selection list made it to the final list, including Fosun Kite's Axicabtagene Ciloleucel Injection, Juventas' Naxiorlen Autologous CD19-Targeted CAR-T Cell Therapy, JW Therapeutics' Relmacabtagene Autoleucel Injection, IASO Bio's Equecabtagene Autoleucel Injection, and CARsgen Therapeutics (subsidiary Kexing Life)'s Zevorcabtagene Autoleucel Injection. (Reporter Xiaoxiao Li from The Paper)